In summary, this meta-analysis indicates preoperative use of SGLT2 inhibitors significantly reduces the risks of CIN, all-cause mortality, MACE, and HF readmission in AMI patients undergoing PCI. The gene discussed is SLC5A2; the disease is cervical squamous intraepithelial neoplasia.